You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,292,954

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,292,954 protect, and when does it expire?

Patent 10,292,954 protects SOHONOS and is included in one NDA.

This patent has thirty-one patent family members in nineteen countries.

Drugs Protected by US Patent 10,292,954

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-001	Aug 16, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA	⤷ Sign Up
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-002	Aug 16, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA	⤷ Sign Up
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-003	Aug 16, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA	⤷ Sign Up
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-004	Aug 16, 2023		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA	⤷ Sign Up
Ipsen	SOHONOS	palovarotene	CAPSULE;ORAL	215559-005	Aug 16, 2023		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,292,954

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011296080	⤷ Sign Up
Brazil	112013004685	⤷ Sign Up
Canada	2809374	⤷ Sign Up
Chile	2013000580	⤷ Sign Up
China	103200937	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.